ZA991393B - Method of treating impotence due to spinal cord injury. - Google Patents

Method of treating impotence due to spinal cord injury.

Info

Publication number
ZA991393B
ZA991393B ZA9901393A ZA991393A ZA991393B ZA 991393 B ZA991393 B ZA 991393B ZA 9901393 A ZA9901393 A ZA 9901393A ZA 991393 A ZA991393 A ZA 991393A ZA 991393 B ZA991393 B ZA 991393B
Authority
ZA
South Africa
Prior art keywords
spinal cord
cord injury
impotence due
treating impotence
male
Prior art date
Application number
ZA9901393A
Other languages
English (en)
Inventor
Murray Craig Mayton
Ian Howard Osterloh
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of ZA991393B publication Critical patent/ZA991393B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrotherapy Devices (AREA)
ZA9901393A 1998-02-23 1999-02-22 Method of treating impotence due to spinal cord injury. ZA991393B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7558098P 1998-02-23 1998-02-23

Publications (1)

Publication Number Publication Date
ZA991393B true ZA991393B (en) 2000-08-22

Family

ID=22126701

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9901393A ZA991393B (en) 1998-02-23 1999-02-22 Method of treating impotence due to spinal cord injury.

Country Status (17)

Country Link
US (1) US20060040935A1 (xx)
EP (1) EP0951908B1 (xx)
JP (1) JPH11315025A (xx)
KR (1) KR19990072798A (xx)
AT (1) ATE279194T1 (xx)
AU (1) AU755402B2 (xx)
CA (1) CA2262268C (xx)
DE (1) DE69921008T2 (xx)
DK (1) DK0951908T3 (xx)
ES (1) ES2226281T3 (xx)
HU (1) HUP9900438A3 (xx)
IL (1) IL128532A0 (xx)
MY (1) MY133446A (xx)
NZ (1) NZ334333A (xx)
PT (1) PT951908E (xx)
TW (1) TW542719B (xx)
ZA (1) ZA991393B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
DE19834506A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Transmucosales therapeutisches System zur Anwendung von Sildenafil
EP1173167A4 (en) 1999-04-30 2004-07-14 Lilly Icos Llc TREATMENT OF FEMALE SEXUAL STIMULATION DISORDERS
PL356848A1 (en) 1999-12-24 2004-07-12 Bayer Aktiengesellschaft Novel imidazo[1,3,5]triazinones and the use thereof
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
WO2002102385A1 (en) * 2001-06-14 2002-12-27 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
KR100393160B1 (ko) * 2001-06-14 2003-07-31 한국과학기술연구원 신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
CN102512681A (zh) 2004-05-11 2012-06-27 情感智能有限责任公司 药物制剂及其在治疗女性性功能障碍中的应用
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2008142396A1 (en) * 2007-05-18 2008-11-27 Anthony Denis Maher Methods of assessing male fertility using a uridine marker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
ES2226281T3 (es) 2005-03-16
ATE279194T1 (de) 2004-10-15
HU9900438D0 (en) 1999-04-28
EP0951908A3 (en) 2000-08-16
EP0951908B1 (en) 2004-10-13
US20060040935A1 (en) 2006-02-23
AU755402B2 (en) 2002-12-12
IL128532A0 (en) 2000-01-31
DE69921008D1 (de) 2004-11-18
PT951908E (pt) 2005-01-31
NZ334333A (en) 2000-11-24
DK0951908T3 (da) 2004-12-27
EP0951908A2 (en) 1999-10-27
TW542719B (en) 2003-07-21
HUP9900438A2 (hu) 2000-03-28
KR19990072798A (ko) 1999-09-27
CA2262268A1 (en) 1999-08-23
DE69921008T2 (de) 2006-02-02
MY133446A (en) 2007-11-30
AU1839099A (en) 1999-09-09
CA2262268C (en) 2003-07-29
JPH11315025A (ja) 1999-11-16
HUP9900438A3 (en) 2002-01-28

Similar Documents

Publication Publication Date Title
ZA991393B (en) Method of treating impotence due to spinal cord injury.
MY117967A (en) Intranasal formulations for treating sexual disorders
MX9703868A (es) Inhibidores de cgmp-pde para el tratamiento de disfuncion erectil.
IL151317A0 (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction
IL153492A0 (en) Treatment of male sexual dysfunction
GC0000096A (en) Treatment of female sexual dysfunction.
WO1994004120A3 (en) Methods of treating sexual dysfunction in animals with and h agonist
NZ270871A (en) Method for treating erectile dysfunction
HU911810D0 (en) Process for the treating of impotency
AU2001250821A1 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
IL151646A0 (en) Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodicesterase 5 for treating erectile dysfunction
WO2003075743A3 (en) Apparatus and method for stabilizing pelvic ring disruption
ID24184A (id) Obat untuk perawatan disfungsi ereksi
EP1150698A4 (en) USES OF THE ENDOTHELIAL VASCULAR GROWTH FACTOR FOR THE TREATMENT OF DYSERECTION
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
IL155775A0 (en) Treatment of male sexual dysfunction
MD1979F1 (en) Method of secondary cataract treatment
GB2277265A (en) Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema
WO2005051368A3 (en) Phosphodiesterase v inhibitor formulations
AU2001281396A1 (en) Novel compositions and methods for treatment of male erectile dysfunction
GB9928178D0 (en) Agent for the treatment of male and female sexual dysfunction
CA2203379A1 (en) Cgmp-pde inhibitors for the treatment of erectile dysfunction
IL101961A0 (en) Use of atipamezole
ECSP993027A (es) Formulaciones intranasales para trastornos sexuales
GEP20043347B (en) Use of Pyrazolopyrimidinones for Treatment of Impotence